Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.
GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...
GlaxoSmithKline Pharmaceuticals reported a significant increase in net profit to Rs 229 crore for the third quarter ending ...
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.80.
The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...
With vaccine hesitancy leading to a rise in measles cases, the FDA's approval of GlaxoSmithKline's venerable vaccine Priorix for sale in the US looks timely. Priorix was first launched in Europe ...
Commenting on the results, Bhushan Akshikar, MD of GlaxoSmithKline Pharmaceuticals, highlighted the company’s strategic initiatives in strengthening its market presence and enhancing access to ...
GlaxoSmithKline share price has surged more than 36% in two sessions after the announcement of Q3 results. The stock has ...
5don MSN
GlaxoSmithKline Pharmaceuticals shares surged 20% to ₹2,421.30 after a strong Q3FY25 performance, reporting a 400% rise in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback